MEN1 T344M

CI-VAR-00004315Explore in graph →NP_001357188.2:p.Thr344MetNM_001370259.2:c.1031C>TClinVar 527269 CIViC 5371 rs1259681826

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Leukemia1
MEN1 T344M	Revumenib + VTP-50469Substitutes	Predictive	B	Supports Resistance	4	submitted	EID12733 Tumor DNA sequencing identified the MEN1 T344M (aka T349M) variant in one patient (#4) on the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targeting five variants identified a tot… (full text at CIViC) PMID 36922589 · Perner et al., 2023 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
527269	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	Multiple endocrine neoplasia, type 1; Hereditary cancer-predisposing syndrome	germline	2	Nov 17, 2025	clinvar